

VU Research Portal

Modulators of proteostasis: therapeutic targets and diagnostic markers to halt and reverse atrial fibrillation

Marion, D.M.S.

2021

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Marion, D. M. S. (2021). *Modulators of proteostasis: therapeutic targets and diagnostic markers to halt and reverse atrial fibrillation: Modulating proteostasis to halt and reverse AF*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Contents

Part I: Introduction

Chapter 1	General introduction and scope of the thesis	9
Chapter 2	The protective role of small heat shock proteins in cardiac diseases: key role in atrial fibrillation <i>Cell Stress Chaperones. 2017 Jul; 22(4):665-674</i>	25
Chapter 3	Diagnosis and therapy of atrial fibrillation: the past, the present and the future <i>Journal of Atrial Fibrillation. 2015 Aug; 8(2):1216</i>	47
Chapter 4	The future of atrial fibrillation therapy: intervention on heat shock proteins influencing electropathology is the next in line <i>Netherlands Heart Journal. 2015 Jun; 23(6):327-33</i>	75
Chapter 5	HALT & REVERSE: Hsf1 Activators Lower cardiomyocyte damage; Towards a novel approach to REVERSE atrial fibrillation <i>Journal of Translational Medicine. 2015 Nov; 13:347</i>	91

Part II: Experimental research

Chapter 6	RhoA activation sensitizes cells to proteotoxic stimuli by abrogating the HSF1-dependent heat shock response <i>PLoS One. 2015 Jul; 10(7):e0133553</i>	107
Chapter 7	Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation <i>Drug Design, Development and Therapy. 2019 Jan; 13:345-36</i>	133

Chapter 8	Heat shock protein inducer GGA*-59 reverses contractile and structural remodeling via restoration of the microtubule network in experimental atrial fibrillation	179
	<i>Journal of Molecular and Cellular Cardiology. 2019 Sep; 134:86-97</i>	
Chapter 9	Oral geranylgeranylacetone treatment increases heat shock protein expression in human atrial tissue	215
	<i>Heart Rhythm. 2020 Jan; 7(1):115-122</i>	
Chapter 10	Evaluating serum heat shock protein levels as novel biomarkers for atrial fibrillation	235
	<i>Cells. 2020 Sep; 9(9):2105</i>	
Chapter 11	Atrial HSP levels are associated with persistent AF, AF recurrence after Maze surgery and post-operative AF	259
	<i>In preparation</i>	
Chapter 12	Mitochondrial dysfunction underlies cardiomyocyte remodeling in experimental and clinical atrial fibrillation	285
	<i>Cells. 2019 Oct; 8(10):1202</i>	
Chapter 13	Cell-free circulating mitochondrial DNA: a potential blood-based marker for atrial fibrillation	329
	<i>Cells. 2020 May; 9(5):1159</i>	

Part III: Epilogue

Chapter 14	Summary	361
Chapter 15	General discussion and future perspectives	367
Addendum	Nederlandse samenvatting	381
	List of publications	
	Acknowledgements / Dankwoord	